Clinical Trials Register

Trials with a EudraCT protocol (395)
Paediatric studies in scope of Art45 of the Paediatric Regulation (2)

395 result(s) found for: Ovarian cysts. Displaying page 1 of 20.

EudraCT Number: 2012-001661-32

Sponsor Protocol Number: VeTo

Start Date*: 2012-07-05

Sponsor Name:Vejle Hospital, Dept. of Oncology

Full Title: Veliparib (ABT888) and Topotecan (Hycamtin®) for Patients with Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer with Negative or Unknown BRCA Status

Medical condition: Relapsed epithelial, platinum resistant ovarian cancer with negative or unknown BRCA status

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10057529	Ovarian cancer metastatic	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066697	Ovarian cancer recurrent	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033128	Ovarian cancer	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: DK (Completed)

Trial results: View results

EudraCT Number: 2014-002014-22

Sponsor Protocol Number: ONK-MAP/AZD2281-01

Start Date*: 2014-05-27

Sponsor Name:Országos Onkológiai Intézet

Full Title: An open label, single center, non-randomised, phase II study of efficacy Olaparib in patients with BRCA mutation posistive previously treated advanced ocarium cancer

Medical condition: advanced ovarian cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10057529	Ovarian cancer metastatic	PT

Population Age: Adults

Gender: Female

Trial protocol: HU (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2020-005091-36

Sponsor Protocol Number: 2020-005091-36

Start Date*: 2021-08-30

Sponsor Name:Stichting Catharina Hospital

Full Title: Signal TrAnsduction Pathway activity analysis for OVarian cancER treatment. STAPOVER study

Medical condition: Ovarian cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033128	Ovarian cancer	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10057529	Ovarian cancer metastatic	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066697	Ovarian cancer recurrent	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033131	Ovarian carcinoma	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10070905	Ovarian cancer stage I	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10070906	Ovarian cancer stage II	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10070907	Ovarian cancer stage III	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10070908	Ovarian cancer stage IV	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10007107	Cancer of ovary	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10026310	Malignant neoplasm of ovary	LLT

Population Age: Elderly

Gender: Female

Trial protocol: NL (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2010-023613-61

Sponsor Protocol Number: IPR/24

Start Date*: 2011-06-13

Sponsor Name:MOLMED

Full Title: NGR018: Randomized phase II study of NGR-hTNF plus pegylated liposomal doxorubicin (PLD) versus PLD in platinum-resistant ovarian cancer

Medical condition: Advanced or metastatic platinum-resistant ovarian cancer patients

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	13.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10057529	Ovarian cancer metastatic	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: IT (Completed) GB (Completed)

Trial results: View results

EudraCT Number: 2008-004429-41

Sponsor Protocol Number: BAY43-9006/12007

Start Date*: 2008-10-03

Sponsor Name:Bayer Healthcare AG

Full Title: A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a ...

Medical condition: The study population will include patients with FIGO stage III or IV ovarian cancer or primary peritoneal cancer who have had extensive debulkment surgery and who have achieved a clinical complete ...

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10052171	Peritoneal carcinoma	LLT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033164	Ovarian epithelial cancer stage IV	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033163	Ovarian epithelial cancer stage III	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: BE (Completed) NL (Completed) IT (Completed) ES (Completed) FR (Completed) FI (Completed) DE (Completed) PL (Completed)

Trial results: View results

EudraCT Number: 2009-017946-30

Sponsor Protocol Number: 20060517

Start Date*: 2011-01-19

Sponsor Name:Amgen Inc.

Full Title: A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Prim...

Medical condition: Recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066697	Ovarian cancer recurrent	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: HU (Completed) GB (Completed) SK (Completed) AT (Prematurely Ended) BE (Completed) IT (Completed) DK (Completed) DE (Completed) PL (Completed) GR (Completed) LV (Completed) ES (Completed) FR (Completed)

Trial results: View results

EudraCT Number: 2016-001755-45

Sponsor Protocol Number: OX4325

Start Date*: 2016-09-12

Sponsor Name:Mateon Therapeutics, Inc.

Full Title: FOCUS: A Multicenter, Multinational, Double-blind, 2-Arm, Randomized, Phase 2/3, Study of Physician’s Choice Chemotherapy (PCC) (Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bev...

Medical condition: Platinum-resistant, recurrent, epithelial ovarian, primary peritoneal or fallopian tube cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	19.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016180	Fallopian tube cancer	PT
	19.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066697	Ovarian cancer recurrent	PT
	19.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033128	Ovarian cancer	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: BE (Completed) DE (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2012-001144-22

Sponsor Protocol Number: ML28337

Start Date*: 2012-07-03

Sponsor Name:ROCHE SAS

Full Title: A RANDOMIZED, OPEN-LABEL, PHASE II STUDY ASSESSING THE EFFICACY AND THE SAFETY OF BEVACIZUMAB IN NEOADJUVANT THERAPY IN PATIENTS WITH FIGO STAGE IIIC/IV OVARIAN, TUBAL OR PERITONEAL ADENOCARCINOMA,...

Medical condition: Epithelial ovarian cancer Fallopian tube carcinoma Primary peritoneal carcinoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000021045	10052204	Ovarian carcinosarcoma	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016180	Fallopian tube cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033128	Ovarian cancer	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: FR (Completed)

Trial results: View results

EudraCT Number: 2009-010095-23

Sponsor Protocol Number: AA-GYN-002

Start Date*: 2009-07-06

Sponsor Name:Omrix Biopharmaceuticals Ltd

Full Title: A prospective, controlled, randomized, multi-center, pivotal study evaluating the safety and efficacy of ADHEXIL in prevention and/or reduction of adhesions in gynecology surgery

Medical condition: Adhesions in gynecology surgery. Surgeries involved will be ovarian cystectomy, endometriosis, inflammation, adhesiolysis Ovarian adhesion MedDRA 10067156 Tubal rupture MedDRA 10067553

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10014778	Endometriosis	LLT
	9.1		10004433	Benign ovarian tumour	LLT
	9.1		10053865	Benign fallopian tube neoplasm	LLT
	9.1		10050697	Fallopian tube cyst	LLT
	9.1		10061855	Fallopian tube neoplasm	LLT
	9.1		10048991	Ovarian adenoma	LLT
	9.1		10033132	Ovarian cyst	LLT
	9.1		10033136	Ovarian cyst ruptured	LLT
	9.1		10064257	Ovarian fibroma	LLT
	9.1		10033236	Ovarian germ cell teratoma benign	LLT
	9.1		10061535	Ovarian neoplasm	LLT
	9.1		10052456	Parovarian cyst	LLT
	9.1		10036049	Polycystic ovaries	LLT
	9.1		10033139	Ovarian disorder	LLT
	9.1		10033263	Ovarian haematoma	LLT
	9.1		10065741	Ovarian haemorrhage	LLT
	9.1		10058823	Ovarian mass	LLT
	9.1		10033277	Ovarian prolapse	LLT
	9.1		10033279	Ovarian rupture	LLT
	9.1		10046988	Varicocele ovarian	LLT
	9.1		10052094	Fallopian tube disorder	LLT
	9.1		10065789	Fallopian tube obstruction	LLT
	9.1		10065790	Fallopian tube perforation	LLT
	9.1		10065791	Fallopian tube stenosis	LLT
	9.1		10050468	Haematosalpinx	LLT
	9.1		10061071	Congenital ovarian anomaly	LLT
	9.1		10061062	Congenital fallopian tube anomaly	LLT
	11.1		10067156		PT
	9.1		10060781	Haemorrhagic ovarian cyst	LLT
	11.1		10067553		PT
	9.1		10033157	Ovarian enlargement	LLT

Population Age: Adults

Gender: Female

Trial protocol: DE (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2016-004850-14

Sponsor Protocol Number: GEICO-1601

Start Date*: 2017-11-13

Sponsor Name:Grupo Español de Investigación en Cancer de Ovario

Full Title: Multicentric Single Arm Phase II Clinical Trial, to Evaluate Safety and Efficacy of the Combination of Olaparib and PLD for Platinum Resistant Ovarian Primary Peritoneal Carcinoma, and Fallopian Tu...

Medical condition: Platinum resistant ovarian primary peritoneal carcinoma, and fallopian tube cancer patients.

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10070908	Ovarian cancer stage IV	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10057529	Ovarian cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066697	Ovarian cancer recurrent	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: ES (Completed)

Trial results: View results

EudraCT Number: 2013-001323-38

Sponsor Protocol Number: SOV02

Start Date*: 2013-08-30

Sponsor Name:SOTIO a.s.

Full Title: A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to standard chemotherapy (carboplatin and gemcitabine) in women with rel...

Medical condition: epithelial ovarian carcinoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061328	Ovarian epithelial cancer	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: CZ (Completed) DE (Completed) PL (Completed)

Trial results: View results

EudraCT Number: 2007-000004-33

Sponsor Protocol Number: IPR/18

Start Date*: 2008-10-13

Sponsor Name:MOLMED

Full Title: NGR012: A phase II study of NGR-hTNF administered in combination with doxorubicin every 3 weeks in patients affected by advanced or metastatic ovarian cancer

Medical condition: Patients affected by advanced or metastatic ovarian cancer previously treated with platinum regimens (cis or carboplatin) plus paclitaxel

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10057529	Ovarian cancer metastatic	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: IT (Completed)

Trial results: View results

EudraCT Number: 2020-004364-25

Sponsor Protocol Number: GINECO-OV244b

Start Date*: 2021-01-08

Sponsor Name:ARCAGY-GINECO

Full Title: Randomized Phase II study comparing neo-epitope based vaccine OSE2101 (TEDOPI®) with or without anti-PD1 (Pembrolizumab) versus best supportive care as maintenance treatment in platinum-sensitive r...

Medical condition: 1st or 2nd platinum-sensitive recurrent ovarian cancer with controlled disease after platinum based chemotherapy.

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033128	Ovarian cancer	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066697	Ovarian cancer recurrent	PT

Population Age: Adults

Gender: Female

Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2013-001325-24

Sponsor Protocol Number: SOV03

Start Date*: 2013-08-30

Sponsor Name:SOTIO a.s.

Full Title: A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to standard chemotherapy in women with relapsed platinum resistant epith...

Medical condition: epithelial ovarian carcinoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	16.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061328	Ovarian epithelial cancer	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: CZ (Completed) DE (Completed) PL (Completed)

Trial results: View results

EudraCT Number: 2010-024631-16

Sponsor Protocol Number: EFC10260

Start Date*: 2011-04-26

Sponsor Name:sanofi-aventis recherche & développement

Full Title: A Phase 2, Multi-Center, Double-Blind, placebo controlled, Randomized Study of Ombrabulin in Patients with Platinum-Sensitive Recurrent Ovarian Cancer treated with Carboplatin/Paclitaxel

Medical condition: Ovarian Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066697	Ovarian cancer recurrent	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: BE (Completed) DE (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) IT (Completed)

Trial results: View results

EudraCT Number: 2010-018693-20

Sponsor Protocol Number: AR HSG 02 2010

Start Date*: 2010-03-18

Sponsor Name:AZIENDA OSPEDALIERA SAN GERARDO DI MONZA

Full Title: Do peritoneal nebulization of Ropivacaine reduce the use of morphine after short gynecologic laparoscopic surgery? A multicentre, randomized, controlled, double blinded, phase III clinical trial; ...

Medical condition: Elective ovarian cyst laparoscopic surgery

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10033132		PT

Population Age: Adults

Gender: Female

Trial protocol: IT (Completed)

Trial results: (No results available)

EudraCT Number: 2008-000878-20

Sponsor Protocol Number: 88248815

Start Date*: 2008-06-20

Sponsor Name:Vejle Sygehus

Full Title: Bevacizumab og Carboplatin til patienter med platinresistent epithelial ovariecancer

Medical condition: Platinresistent epithelial ovarie cancer eller primær peritoneal ovarie cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	16.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033160	Ovarian epithelial cancer recurrent	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: DK (Completed)

Trial results: (No results available)

EudraCT Number: 2013-005471-40

Sponsor Protocol Number: CFTSp074

Start Date*: 2014-08-12

Sponsor Name:The Christie NHS Foundation Trust

Full Title: PAZOFOS: A Phase Ib and Randomised Phase II Trial of Pazopanib with or without Fosbretabulin in Advanced Recurrent Ovarian Cancer

Medical condition: partially platinum resistant ovarian cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10057529	Ovarian cancer metastatic	PT
	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066697	Ovarian cancer recurrent	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: GB (Prematurely Ended)

Trial results: View results

EudraCT Number: 2018-003346-17	Sponsor Protocol Number: M17OVH	Start Date*: 2019-04-18
Sponsor Name:NKI-AVL
Full Title: Phase III Randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy: OVHIPEC-2
Medical condition: stage III epithelial ovarian cancer
Disease:
Population Age: Adults, Elderly		Gender: Female
Trial protocol: NL (Ongoing) FR (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2010-019525-34

Sponsor Protocol Number: MO22923

Start Date*: 2010-12-17

Sponsor Name:F. Hoffmann-La Roche Ltd

Full Title: GLOBAL STUDY TO ASSESS THE ADDITION OF BEVACIZUMAB TO CARBOPLATIN AND PACLITAXEL AS FRONT-LINE TREATMENT OF EPITHELIAL OVARIAN CANCER, FALLOPIAN TUBE CARCINOMA OR PRIMARY PERITONEAL CARCINOMA

Medical condition: EPITHELIAL OVARIAN CANCER FALLOPIAN TUBE CARCINOMA PRIMARY PERITONEAL CARCINOMA

Disease:	Version	SOC Term	Classification Code	Term	Level
	12.1		10033128	Ovarian cancer	LLT
	12.1		10052204	Ovarian carcinosarcoma	LLT
	12.1		10016180	Fallopian tube cancer	LLT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: SK (Completed) FR (Completed) ES (Completed) LT (Completed) AT (Completed) LV (Completed) NL (Completed) IE (Completed) SE (Completed) EE (Completed) HU (Completed) IT (Completed) BG (Completed) DK (Completed) SI (Completed) GR (Completed) PT (Completed) PL (Completed)

Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials for Ovarian cysts